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Sex Med 2Introduction: Peyronie’s disease (PD) and Dupuytren contractures (DC) are often comorbid and are believed to
have a similar underlying pathophysiologic mechanism.
Aim: To investigate the prevalence of PD-like symptoms (PDLS) in men with DC.
Methods: From October 2013 to December 2016, men who were seen and evaluated for DC were offered the
opportunity to participate in an anonymous survey. The survey assessed several basic demographic and sexual
health factors and included items from the International Index of Erectile Function and the Erection Hardness
Scale. Men who reported PDLS were asked a series of questions derived from the Peyronie’s Disease Ques-
tionnaire and for their opinions on theoretical treatment modalities for sexual problems and penile deformity.
Main Outcome Measure: Prevalence of PDLS in men with DC.
Results: One hundred forty men with DC were invited to participate; 85 surveys were returned (response rate ¼
61%). Twenty-two respondents (26%, 95% confidence interval ¼ 17e35) reported PDLS. Approximately one
fourth of all respondents had an Erection Hardness Scale score lower than 3. The most common specific PDLS
concerns were penile curvature (91%), length loss (55%), narrowing (36%), and hinging (32%). In men with
PDLS, 73% felt at least a little bothered by the symptoms when attempting sexual activity and 40% reported having
sex less frequently because of the symptoms. Just 27% of men with PDLS had ever used a treatment for a sexual
concern. In terms of treatments for penile deformities, 64% of men with PDLS expressed an interest in treatment
administered in the form of an in-office procedure; 41% were potentially amenable to a surgical procedure.
Conclusion: The prevalence of PDLS in men with DC is similar to the prevalence of DC in men diagnosed with
PD. A substantial number of these men have distress and would consider standard-of-care treatments for PD.
Shindel AW, Sweet G, Thieu W, et al. Prevalence of Peyronie’s Disease-Like Symptoms in Men Presenting
With Dupuytren Contractures. Sex Med 2017;5:e135ee141.
Copyright  2017, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Peyronie’s disease (PD; known historically as induratio penis
plastica) is a potentially debilitating condition of penile deformity
often accompanied by pain, curvature, loss of length, and erectile
dysfunction (ED). The condition is believed to be related to
abnormal collagen deposition within the penis.1,2
The prevalence of penile plaque in populations screened by
trained examiners has been reported as high as 7% to 9%,3,4
although the percentage of such patients who present for treat-
ment is much smaller. PD is markedly more common in older
men but has been reported in young men, including teenagers.5,6
PD also is associated with other collagen deposition disorders
such as tympanosclerosis, Lederhosen syndrome, and Dupuytrene135
e136 Shindel et alcontractures (DC) of the hands.1,2 Gene expression analysis has
suggested substantial overlap between DC and PD lesions,7
indicating that a genetic predisposition to fibrotic conditions
could contribute to the two conditions.
A clinical association between PD and DC was reported as
long ago as 1828.8 A 2011 study reported the prevalence of DC
in men with PD at 22%.9 Despite this established relation and
emerging evidence on the prevalence of DC in PD, the preva-
lence of PD in men with DC has not, to our knowledge, been
reported. In this pilot study we report on the prevalence of
symptoms consistent with the diagnosis of PD in a population of
men confirmed to have DC. We hypothesized that the preva-
lence of PD-like symptoms (PDLS) would be similar (eg,
approximately 22%) to what has been reported for the prevalence
of DC in PD. Exploratory end points included assessments of
demographic and health factors and the relative bother and
interest in therapies for men with PDLS.METHODS
Study Population
Eligible men were identified from those presenting for evalu-
ation at an orthopedic hand specialty clinic at a major academic
medical center. An experienced orthopedic hand specialist eval-
uated all patients presenting with symptoms possibly consistent
with DC. Those confirmed to have DC were offered the
opportunity to participate in an anonymous survey. Interested
men were provided a paper survey and given the option of
completing and returning it immediately or mailing it to the
research coordinator in a self-addressed stamped envelope. The
study was open for enrollment from October 2013 to December
2016. To preserve anonymity, written informed consent was not
obtained; informed consent was implied from completion
and return of the survey. No inducement was provided. The
institutional review board approved this study.Survey
The survey instrument is presented in Appendix 1. We
collected data on age, race, cigarette use, number of hands
affected by DC, and comorbid conditions that have been asso-
ciated with PD (ie, diabetes, hypertension, high cholesterol,
gout, rheumatoid arthritis, nodules on the feet, or scarring of the
inner ear). Men also were asked to complete the Erection
Hardness Scale (EHS; four-point unipolar Likert scale)10 and
question 7 of the International Index of Erectile Function (IIEF)
using a five-point unipolar Likert scale pertaining to the
frequency of satisfactory sexual intercourse during the past 4
weeks with a sixth option for absence of sexual activity.11
Patients were asked if they had noted any changes in their
penis after puberty; this time scale was selected to screen out
congenital conditions such as chordee and normal changes in
penile morphology that occur with puberty. Men who replied in
the affirmative were considered at risk for PDLS and were askedanother battery of questions regarding age of onset, specific type
of changes noted, prior use of any sort of treatment to assist with
sexual dysfunction, and willingness to consider treatment for
penile morphologic changes. Men were asked to rate their will-
ingness to use oral medications, office-based procedures, and
surgical procedures to address the penile deformity; response
options were based on a five-item bipolar Likert scale. Several
items from the Peyronie’s Disease Questionnaire (PDQ) also
were included in this survey. Specifically, men were asked
question 13 (pertaining to bother at last attempt to have sexual
activity), question 14 (pertaining to having sex less often), and
question 15 (pertaining to bother from having sex less often).12
For sake of inclusion, all PDQ questions were modified from the
original to be non-specific for vaginal intercourse.Statistical Methods
Data analysis was conducted using R 3.3.1 (R Core Team,
Vienna, Austria). Descriptive statistics (mean, SD, median, and
range) were used for continuous variables, and categorical vari-
ables were summarized by number and percentage. Fisher exact
test was used to test for the association between risk factors and
PDLS. Given the sample size, multivariable analysis was not
advisable. Any P values less than .05 were considered statistically
significant and all statistical tests were two-sided. A 95% confi-
dence interval for the prevalence of PDLS in this population was
calculated using the normal approximation to the binomial
distribution.
The primary outcome variable was prevalence of PDLS in men
with confirmed DC. Secondary variables included specific
manifestations of PDLS, degree of sexual bother (derived from
elements of the EHS, IIEF, and PDQ), and interest in hypo-
thetical therapies for PDLS.RESULTS
Of men presenting for evaluation during the study enrollment
period, 140 were confirmed to have DC and were invited to
participate. Of these, 85 (61%) completed at least one question
and returned the survey. Twenty-two men (26%) reported
PDLS. The 95% confidence interval for estimation of PDLS in
this population was 17% to 35%.
Demographic and comorbidity data are presented in Table 1.
Men with and without PDLS were generally similar in their
demographics and comorbidities. There were no statistically
significant differences in these variables between men with and
those without PDLS (P > .05).
Data on EHS scores and sexual satisfaction are presented in
Table 2. The overall prevalence of an EHS score of 3 or 4 was
similar between groups (75% and 77% for those without and
with PDLS), although men in this group with PDLS tended to
have an EHS score of 3 more frequently than those without
PDLS. Sexual inactivity was slightly more common in men
without PDLS (32% vs 18% for those without vs with PDLS,Sex Med 2017;5:e135ee141
Table 1. Demographic and comorbidity data
No PD signs or
symptoms (n ¼ 63)
PD signs or
symptoms (n ¼ 22)
All patients
(N ¼ 85) P value*
Demographics
Current age (y) .930
n 61 21 82
Mean (SD) 65.1 (9.2) 65 (8.6) 65.1 (9)
Median (range) 65 (44e84) 64 (46e76) 65 (44e84)
Race, n (%)
African-American or black 2 (3.2) 0 2 (2.4) .706
American Indian, Native American,
or Alaskan Native
1 (1.6) 1 (4.5) 2 (2.4)
European-American or white 60 (95.2) 21 (95.5) 81 (95.3)
Cigarette smoking, n (%) >.999
No 61 (96.8) 22 (100) 83 (97.6)
Yes 2 (3.2) 0 2 (2.4)
Comorbidities, n (%)
Hands with DC .165
2 hands 18 (28.6) 3 (13.6) 21 (24.7)
1 hand 27 (42.9) 15 (68.2) 42 (49.4)
Not reported 18 (28.6) 4 (18.2) 22 (25.9)
Diabetes .274
No 52 (82.5) 21 (95.5) 73 (85.9)
Yes 10 (15.9) 1 (4.5) 11 (12.9)
Not reported 1 (1.6) 0 1 (1.2)
High blood pressure .806
No 36 (57.1) 12 (54.5) 48 (56.5)
Yes 26 (41.3) 10 (45.5) 36 (42.4)
Not reported 1 (1.6) 0 1 (1.2)
High cholesterol >.999
No 27 (42.9) 9 (40.9) 36 (42.4)
Yes 36 (57.1) 13 (59.1) 49 (57.6)
Inner ear scarring .262
No 62 (98.4) 21 (95.5) 83 (97.6)
Yes 0 1 (4.5) 1 (1.2)
Not reported 1 (1.6) 0 1 (1.2)
Nodules on feet >.999
No 53 (84.1) 20 (90.9) 73 (85.9)
Yes 7 (11.1) 2 (9.1) 9 (10.6)
Not reported 3 (4.8) 0 3 (3.5)
Gout >.999
No 53 (84.1) 19 (86.4) 72 (84.7)
Yes 8 (12.7) 3 (13.6) 11 (12.9)
Not reported 2 (3.2) 0 2 (2.4)
Rheumatoid arthritis >.999
No 57 (90.5) 21 (95.5) 78 (91.8)
Yes 3 (4.8) 1 (4.5) 4 (4.7)
Not reported 3 (4.8) 0 3 (3.5)
DC ¼ Dupuytren contractures; PD ¼ Peyronie’s disease.
*P values are from a two-sample t-test for age and Fisher exact test for categorical variables.
Prevalence of PDLS in Men With DC e137respectively), although this difference did not achieve statistical
significance (P ¼ .280). The rate of satisfaction with sex “most”
or “all” the time was similar between groups (64% for both
groups).Sex Med 2017;5:e135ee141Data on timing and nature of penile morphologic changes in
men who reported PDLS are presented in Table 3. Curvature
with erection was the most common complaint (n ¼ 20, 91%),
with loss of length (n ¼ 12, 55%), shaft narrowing (n ¼ 8,
Table 2. Data on EHS and sexual satisfaction
No PD signs or
symptoms (n ¼ 63)
PD signs or
symptoms (n ¼ 22)
All patients
(N ¼ 85) P value*
How hard does your penis get when you are sexually
excited (turned on?)
.507
I have not had any sexual excitement 1 (1.6%) 0 1 (1.2%)
My penis gets very hard and rigid (EHS score ¼ 4) 30 (47.6%) 7 (31.8%) 37 (43.5%)
My penis gets hard enough for sex but is not totally
hard (EHS score ¼ 3)
17 (27.0%) 10 (45.5%) 27 (31.8%)
My penis gets larger and firm but not hard enough for
sex (EHS score ¼ 2)
9 (14.3%) 2 (9.1%) 11 (12.9%)
My penis gets larger but not hard (EHS score ¼ 1) 5 (7.9%) 3 (13.6%) 8 (9.4%)
No erection at all 1 (1.6%) 0 1 (1.2%)
When you had sex during the past month, how often
was it satisfactory for you?
.187
Almost never or never 1 (1.6%) 0 1 (1.2%)
A few times 1 (1.6%) 3 (13.6%) 4 (4.7%)
Sometimes 1 (1.6%) 1 (4.5%) 2 (2.4%)
Most time 11 (17.5%) 4 (18.2%) 15 (17.6%)
Almost always or always 29 (46%) 10 (45.5%) 39 (45.9%)
I have not had sex in the past month 20 (31.7%) 4 (18.2%) 24 (28.2%)
EHS ¼ Erection Hardness Scale; PD ¼ Peyronie’s disease.
*By Fisher exact test.
e138 Shindel et al36%), hinging or weakness (n ¼ 7, 32%), and pain with erection
(n ¼ 5, 23%) also common. At least some element of bother was
reported by 17 (73%) of these men and 9 (41%) reported that
they were having sex less often because of PDLS. Of these nine,
five reported that they were “very” or “extremely” bothered.
Data on prior treatment for sexual concerns and theoretical
interest in treatment in men who reported PDLS are presented in
Table 4. Slightly more than one fourth of men reported having
used a treatment for sexual concerns, with oral pharmacotherapy
the most frequently used option. Patients reported being
amenable (defined as “maybe,” “probably yes,” or “definitely
yes”) to considering therapy for PDLS in the form of an oral pill
(19 patients, 86%), office procedure (14 patients, 64%), or
surgical procedure (9 patients, 41%).DISCUSSION
To our knowledge, these data represent the first analysis of the
prevalence of bothersome, acquired changes in penile
morphology in men with DC. Our response rate was 61%,
which is high for an uncompensated survey. Consistent with our
hypothesis, the rate of PDLS in this population was 26%. A
substantial proportion of these men reported distress related to
the condition and a willingness to consider treatment, including
treatments that are currently available and supported by major
guidelines (eg, intralesional collagenase and surgical correction of
penile curvature).13
PD and DC are similar in that they are fibrotic disorders
related to abnormal deposition of collagen in connectivetissues.1,2 Upregulation in genes related to collagen degradation,
ossification, and myofibroblast differentiation has been reported
in DC and PD tissues.7 Given similarities in phenotype and
genetic drivers of these two conditions, it is not surprising that
these conditions often might be comorbid.
This cohort was predominantly Caucasian, which is
consistent with the reported racial makeup of patients with PD
and those with DC. The prevalence of various health condi-
tions is within expected ranges for a cohort of men with mean
age approximately 65 years; this also applies to the prevalence
of ED in the study population14 (estimated in this study by
EHS score  2). PD has been historically associated with
Caucasian race15 and health factors including tobacco use.3,16
PD also is often comorbid with risk factors for ED (eg, dia-
betes, hypertension, and hyperlipidemia).16e18 Interestingly,
one study suggested that hyperlipidemia and obesity (risk
factors for ED) were inversely associated with PD.15 We could
not perform analysis on PDLS as a factor of ethno-
demographic or health factors, but the existing literature im-
plies that some of these conditions might have modulated the
prevalence of PD in this cohort.
A substantial proportion of men from this cohort (with and
without PDLS) had not been sexually active in the past month.
The reason for absence of sexual activity was not elucidated in
this study. Of those who were sexually active, most men in the
two groups reported being usually or always satisfied with sexual
encounters but a significant minority of men had less reliable
satisfaction with sexual encounters. Although the reason for at
least occasional lack of satisfaction with sex was not elucidated asSex Med 2017;5:e135ee141
Table 3. Peyronie’s symptoms in men reporting Peyronie’s
disease-like symptoms
How old (in years) were you when you first
noticed the change in your erect
penis? (n ¼ 20)
Mean (SD) 49.3 (16)
Median (range) 53.5 (11e72)
What changes have you noted in your
penis when it is erect?
Loss of length
No 7 (31.8%)
Yes 12 (54.5%)
Not reported 3 (13.6%)
Lumps under the skin
No 15 (68.2%)
Yes 4 (18.2%)
Not reported 3 (13.6%)
Curvature when erect
No 1 (4.5%)
Yes 20 (90.9%)
Not reported 1 (4.5%)
Narrowing along the shaft
No 12 (54.5%)
Yes 8 (36.4%)
Not reported 2 (9.1%)
Hinging or weakness of the shaft
No 12 (54.5%)
Yes 7 (31.8%)
Not reported 3 (13.6%)
Pain with erection
No 14 (63.6%)
Yes 5 (22.7%)
Not reported 3 (13.6%)
Pain with sex
No 15 (68.2%)
Yes 4 (18.2%)
Not reported 3 (13.6%)
Something else
Diminished intensity of orgasm 1 (4.5%)
Loss of girth or diameter. Used to bend left
without lumps but was not evenly thick
1 (4.5%)
None reported 20 (90.9%)
Thinking about the last time you had or
tried to have sex, how bothered were
you by the change(s) in your penis?
Not at all bothered 5 (22.7%)
A little bothered 8 (36.4%)
Moderately bothered 2 (9.1%)
Very bothered 5 (22.7%)
Extremely bothered 1 (4.5%)
Not reported 1 (4.5%)
Are you having sex less often because
of the change in your penis?
No 12 (54.5%)
Yes 9 (40.9%)
Not reported 1 (4.5%)
(continued)
Table 3. Continued
How bothered are you by having sex
less often?
Not at all bothered 0
A little bothered 1 (4.5%)
Moderately bothered 3 (13.6%)
Very bothered 4 (18.2%)
Extremely bothered 1 (4.5%)
Sex Med 2017;5:e135ee141
Prevalence of PDLS in Men With DC e139a factor of the IIEF question, 40% of men with PDLS reported
bother from less frequent sex specifically referable to the condi-
tion. Furthermore, 73% reported bother related to PDLS when
engaging in sexual activity.
Relatively few patients had used any therapy for sexual con-
cerns. More germane to the present analysis, many patients
expressed interest in therapy for PDLS. Oral therapy for PDLS
had the most interest; unfortunately, there is no oral PD therapy
that has robust evidence of efficacy.13 However, many patients
reported that they would consider an in-office procedure
(eg, intralesional injections) and/or surgical correction of
deformity.13
Several important limitations must be discussed. Participa-
tion in this survey was voluntary; we have no reason to suspect
that the population of men who did not complete it differed
from the population that did but we cannot know this for
certain. Patients who declined participation could have been
satisfied with their sexual lives and disinterested in discussing it
or they had no particular issues and did not see utility in
participating. In either case, we acknowledge that this is a self-
selected study but feel positively about the 61% response rate
for an uncompensated survey. Given the small sample, there is
a relatively wide confidence interval for our prevalence esti-
mate. The 26% estimate of PDLS in men with DC should be
viewed as preliminary. However, the data suggest that the
prevalence of PDLS is consistent with our stated hypothesis.
The relatively high event rate mitigates to some extent the
limitations of the small sample; furthermore, the 95% confi-
dence interval of PDLS with a lower bound of 17% indicates
that even with conservative estimates a substantial proportion
of men with DC are experiencing concerning symptoms
relating to their penis. The sample size also limits the potential
for analysis of demographics and comorbid conditions as
modulators of the PD prevalence. Men who reported PDLS
had neither a focused history nor physical examination to
confirm the presence or absence of PD; we cannot estimate
from these data the prevalence of actual PD. Regardless of how
many of these men would have been confirmed to have PD, it
is clear that a substantial number of men with DC have con-
cerns about their penis and/or sexual health and are interested
in available treatment options. In the population of men who
did not have PDLS, approximately one third had not had
sexual activity in the past month; whether these men had
Table 4. Treatment preferences in men with Peyronie’s disease-
like symptoms
Have you ever used a treatment to help
you with problems having sex?
No 15 (68.2%)
Yes 6 (27.3%)
Not reported 1 (4.5%)
What treatments have you used to help
with problems having sex?
Pills from a doctor (eg, Viagra,
Levitra, Cialis)
No 1 (4.5%)
Yes 5 (22.7%)
Not applicable or not reported 16 (72.7%)
Non-prescription pills (eg, herbals)
No 4 (18.2%)
Yes 2 (9.1%)
Not applicable or not reported 16 (72.7%)
Penile injections (eg, Edex, Caverject, bi-mix)
No 6 (27.3%)
Yes 0 (0%)
Not applicable or not reported 16 (72.7%)
Penis pump (vacuum erection device)
No 6 (27.3%)
Yes 0 (0%)
Not applicable or not reported 16 (72.7%)
MUSE (pill that goes inside the penis)
No 6 (27.3%)
Yes 0 (0%)
Not applicable or not reported 16 (72.7%)
Surgery
No 5 (22.7%)
Yes 1 (4.5%)
Not applicable or not reported 16 (72.7%)
If there was a treatment for curvature,
nodules, bends, or other deformities
of the penis, would you use it if .
Treatment was a pill to take by mouth?
Definitely no 1 (4.5%)
Probably no 0
Maybe 8 (36.4%)
Probably yes 5 (22.7%)
Definitely yes 6 (27.3%)
Not reported 2 (9.1%)
Treatment required a procedure in a
clinic office under local anesthetic?
Definitely no 1 (4.5%)
Probably no 5 (22.7%)
Maybe 8 (36.4%)
Probably yes 2 (9.1%)
Definitely yes 4 (18.2%)
Not reported 2 (9.1%)
Treatment required a surgery in an operating
room under general anesthesia?
Definitely no 5 (22.7%)
Probably no 6 (27.3%)
(continued)
Table 4. Continued
Maybe 6 (27.3%)
Probably yes 1 (4.5%)
Definitely yes 2 (9.1%)
Not reported 2 (9.1%)
MUSE ¼ medicated urethral suppository for erections.
e140 Shindel et alexperienced a prolonged period of abstinence that might have
masked PDLS is unclear and cannot be gleaned from these
data.CONCLUSIONS
Many men with DC have bothersome symptoms consistent
with PD. Hand specialists and primary care physicians should
be aware of the relation between PD and DC and should inquire
about sexual and penile health in men with DC. When
appropriate, referral to a sexual medicine specialist should be
initiated.Corresponding Author: Alan W. Shindel, MD, MAS,
Department of Urology, University of CaliforniaeDavis, Sacra-
mento, CA 95817, USA; E-mail: awshindel@ucdavis.edu
Conflicts of Interest: The authors report no conflicts of interest.
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